» Articles » PMID: 30954415

Notch3 Signaling Activation in Smooth Muscle Cells Promotes Extrauterine Growth Restriction-induced Pulmonary Hypertension

Overview
Publisher Elsevier
Date 2019 Apr 8
PMID 30954415
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Early postnatal life is a critical developmental period that affects health of the whole life. Extrauterine growth restriction (EUGR) causes cardiovascular development problems and diseases, including pulmonary arterial hypertension (PAH). PAH is characterized by proliferation, migration, and anti-apoptosis of pulmonary artery smooth muscle cells (PASMCs). However, the role of PASMCs in EUGR has not been studied. Thus, we hypothesized that PASMCs dysfunction played a role in EUGR-induced pulmonary hypertension.

Methods And Results: Here we identified that postnatal nutritional restriction-induced EUGR rats exhibited an elevated mean pulmonary arterial pressure and vascular remodeling at 12 weeks old. PASMCs of EUGR rats showed increased cell proliferation and migration features. In EUGR-induced PAH rats, Notch3 signaling was activated. Relative mRNA and protein expression levels of Notch3 intracellular domain (Notch3 ICD), and Notch target gene Hey1 in PASMCs were upregulated. We further demonstrated that pharmacological inhibition of Notch3 activity by using a γ-secretase inhibitor DAPT, which blocked the cleavage of Notch proteins to ICD peptides, could effectively inhibit PASMC proliferation. Specifically knocked down of Notch3 in rat PASMCs by shRNA restored the abnormal PASMC phenotype in vitro. We found that administration of Notch signaling inhibitor DAPT could successfully reduce mean pulmonary arterial pressure in EUGR rats.

Conclusions: The present study demonstrated that upregulation of Notch3 signaling in PASMCs was crucial for the development of EUGR-induced PAH. Blocking Notch3-Hey1 signaling pathway in PASMCs provides a potential therapeutic target for PAH.

Citing Articles

The Intersection of HIV and Pulmonary Vascular Health: From HIV Evolution to Vascular Cell Types to Disease Mechanisms.

Garcia A, Almodovar S J Vasc Dis. 2024; 3(2):174-200.

PMID: 39464800 PMC: 11507615. DOI: 10.3390/jvd3020015.


Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).

Chen M, Li H, Li Y, Luo Y, He Y, Shui X Int J Mol Med. 2024; 54(6).

PMID: 39422043 PMC: 11518579. DOI: 10.3892/ijmm.2024.5439.


Unraveling the Mfn2-Warburg effect nexus: a therapeutic strategy to combat pulmonary arterial hypertension arising from catch-up growth after IUGR.

Yan L, Luo X, Hang C, YuWang , Zhang Z, Xu S Respir Res. 2024; 25(1):328.

PMID: 39223619 PMC: 11370119. DOI: 10.1186/s12931-024-02957-1.


Inhibition of Notch3/Hey1 ameliorates peribiliary hypoxia by preventing hypertrophic hepatic arteriopathy in biliary atresia progression.

Chang X, Chi S, Zhang X, Li X, Yu C, Zhou Y Histochem Cell Biol. 2024; 161(6):461-476.

PMID: 38597939 DOI: 10.1007/s00418-024-02278-w.


Naked cuticle homolog 1 prevents mouse pulmonary arterial hypertension via inhibition of Wnt/β-catenin and oxidative stress.

Wei S, Lin L, Jiang W, Chen J, Gong G, Sui D Aging (Albany NY). 2023; 15(20):11114-11130.

PMID: 37857014 PMC: 10637826. DOI: 10.18632/aging.205105.